Abstract
The treatment of symptomatic primary hyperparathyroidism (pHPT) is surgical. Medical therapy has a role for the patient who does not want to, or cannot, be operated on: in these cases hypercalcemia is controlled with cinacalet and the bone mineral density (BMD) is improved with bisphosphonates.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Crouzeix G, Kerlan V (2014) Primary hyperparathyroidism: new concepts, new recommendations. Ann Endocrinol (Paris) 75(Suppl 1):S21-S36
Bilezikian JP, Brandi ML, Eastell R et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol 99(10):3561–3569
Köhler BB, Philippe J (2015) News in endocrinology: Management of asymptomatic primary hyperparathyroidism in 2014. Rev Med Suisse 11(456-457):58–61
Marcocci C, Bollerslev J, Khan AA et al (2014) Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop of the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 99(10):3607–3185
Singh Ospina N, Thompson GB, Lee RA et al (2015) Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 100(1):e87-e90
National Institutes of Health (1990) Diagnosis and management of asymptomatic primary hyperparathyroidism. NIH Consensus Development Conference. October 29-31, 1990. NIH Consens Statement 8(7): 1–18
Udelsman R, Akerstrom G, Biagini C et al (2014) The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3595–3606
Bilezikian JP, Khan AA, Potts JT Jr (2009) Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94(2):335–339
Siverberg SJ, Clarke BL, Peacock M et al (2014) Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3580–3594
Agarwal G, Nanda G, Kapoor A et al (2012) Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy: results of a prospective case control study. Surgery 154(6):1394–1403
Pasieka JL (2013) The time has come to redefine the classic symptoms of primary hyperparathyroidism: comment on “parathyroidectomy, elevated depression scores, and suicidal ideation in patients with primary hyperparathyroidism”. JAMA 148(2):115–116
Åberg V, Norenstedt S, Zedenius J et al (2015) Health related quality of life after successful surgery for primary hyperparathyroidectomy: no additive effect from vitamin D supplementation: results of a double-blind randomized study. Eur J Endocrinol 172(2):181–187
Brito K, Edirimanne S, Eslick GD (2015) The extent of improvement of health-related quality of life as assessed by the SF36 and Paseika scales after parathyroidectomy in patients with primary hyperparathyroidectomy—a systematic review and meta-analysis. Int J Surg 13:245–249
Gopinath P, Sadler GP, Mihai R (2010) Persistent symptomatic improvement in the majority of patients undergoing parathyroidectomy for primary hyperparathyroidism. Langenbecks Arch Surg 395(7):941–946
Blanchard C, Mathonnet M, Sebag F et al (2014) Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study. Ann Surg Oncol 21(11):3534–3540
Yeh MW, Wiseman JE, Ituarte PH et al (2012) Surgery for primary hyperparathyroidism: are the consensus guidelines being followed? Ann Surg 255(6):1179–1183
Aliabadi-Wahle S, Kelly TL, Rozenfeld Y et al (2014) Treatment strategies for primary hyperparathyroidism: what is the cost? Am Surg 80(11):1146–1151
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Italia
About this chapter
Cite this chapter
Camandona, M. (2016). Management of Primary Hyperparathyroidism. In: Gasparri, G., Palestini, N., Camandona, M. (eds) Primary, Secondary and Tertiary Hyperparathyroidism. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5758-6_8
Download citation
DOI: https://doi.org/10.1007/978-88-470-5758-6_8
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5757-9
Online ISBN: 978-88-470-5758-6
eBook Packages: MedicineMedicine (R0)